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Abstract: The purpose of this study was to investigate the expression of sarcosine metabolism-related proteins ac-
cording to thyroid cancer subtypes and the implications of these findings. We performed tissue microarrays of 557 
thyroid cancer cases (papillary thyroid carcinoma [PTC]: 344, follicular carcinoma [FC]: 112, medullary carcinoma 
[MC]: 70, poorly differentiated carcinoma [PDC]: 23, and anaplastic carcinoma [AC]: 8) and 152 follicular adenoma 
cases. Immunohistochemical staining for sarcosine metabolism-related molecules [glycine N-methyltransferase 
(GNMT), sarcosine dehydrogenase (SARDH), and l-pipecolic acid oxidase (PIPOX)] was conducted, and the results 
were analyzed based on clinicopathologic parameters. Results: The expression of SARDH and PIPOX was differ-
ent depending on thyroid cancer subtypes. PTC showed higher expression than other subtypes (P<0.001). Among 
PTC, follicular variant (FV) showed lower expression than conventional type (P = 0.010 and P<0.001) and PTC with 
BRAF V600E mutation showed higher expression than PTC without BRAF V600E mutation (P<0.001). In univariate 
analysis, PIPOX positivity was associated with shorter overall survival (OS) in PTC (P = 0.024). In conclusion, the 
expression of sarcosine metabolism-related proteins varied according to thyroid cancer subtypes. SARDH and PIPOX 
showed higher expression in PTC; among PTC, FVPTC showed lower expression and PTC with BRAF V600E mutation 
showed higher expression.
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Introduction
Sarcosine (N-methylglycine) is a non-proteino-
genic amino acid created during glycine synthe-
sis and degradation. The major enzymes 
involved in the sarcosine metabolism pathway 
are glycine N-methyltransferase (GNMT), sarco-
sine dehydrogenase (SARDH), and l-pipecolic 
acid oxidase (PIPOX). Sarcosine is formed by 
transferring the methyl group from S-adeno- 
sylmethionine to glycine via the enzyme GNMT. 
Sarcosine-metabolizing enzymes SARDH and 
PIPOX make glycine via oxidative demethylation 
of sarcosine [1]. Sarcosine has been reported 
to be a potential oncometabolite [2, 3]. In par-
ticular, sarcosine in prostate cancer was shown 
to be a sensitive tumor biomarker and to be 
associated with tumor progression and metas-
tasis [2, 3].
Thyroid cancer is a common malignancy, 
accounting for about 1% of the total population. 
The common subtypes are papillary thyroid car-
cinoma (PTC), follicular carcinoma (FC), medul-
lary carcinoma (MC), poorly differentiated carci-
noma (PDC), and anaplastic carcinoma (AC). 
Cell origin, clinical manifestation, metastatic 
pattern, and clinical prognosis vary according to 
subtypes [4]. The expression of sarcosine-
metabolizing enzymes was reported in other 
endocrine-related cancers such as prostate 
cancer and breast cancer [5, 6], and it was 
found to be associated with tumor progression 
and metastasis [5]. Previous studies revealed 
that thyroid hormone is related to regulation of 
the enzymes involved in methyl group metabo-
lism such as GNMT [7]. The presence of sarco-
sine-metabolizing enzymes in thyroid cancer is 
thus highly likely. However, a direct investiga-
tion has not been previously performed. The 
purpose of this study was thus to investigate 
the expression of sarcosine metabolism-relat-
ed proteins according to thyroid cancer sub-
types and to elucidate potential implications.
Materials and methods
Patient selection
For PTC, we included patients who underwent 
surgery after the diagnosis of PTC at Severance 
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Hospital between January 2012 and December 
2013. For other subtypes, we included patients 
who underwent surgery and were diagnosed 
at Severance Hospital between January 2000 
and December 2014. Patients treated with 
neoadjuvant chemotherapy were excluded. 
This study was approved by the Institutional 
Review Board of Yonsei University Severance 
Hospital. All cases were retrospectively re- 
viewed by a thyroid pathologist (Koo JS), and 
histologic review was performed on Hema- 
toxylin-Eosin (H&E)-stained slides. Clinicopath- 
ologic data were obtained from patient medical 
records and included age at diagnosis, disease 
recurrence, metastasis, current status, and 
length of follow-up. Tumor size, location (right or 
left lobe), extent (confined to the thyroid paren-
chyma or with extrathyroidal spread) and num-
ber of metastatic lymph nodes were also 
recorded from slide review and surgical pathol-
ogy reports.
Tissue microarray
Representative areas were selected on H&E-
stained slides, and a corresponding spot was 
marked on the surface of the matching paraffin 
block. Five-millimeter core biopsies were taken 
from selected areas and placed into a 5×4-mm 
recipient block. More than two tissue cores 
were extracted from each case to minimize 
extraction bias. Each tissue core was assigned 
a unique tissue microarray location number 
that was linked to a database containing other 
clinicopathologic data.
Immunohistochemistry 
Antibodies used for immunohistochemistry are 
listed in Table 1. All immunohistochemistry was 
performed with formalin-fixed, paraffin-embed-
ded tissue sections using an automatic immu-
nohistochemistry staining device (Benchmark 
XT, Ventana Medical Systems, Tucson, AZ, 
USA). Briefly, 5-µm-thick formaldehyde fixed 
paraffin-embedded tissue sections were trans-
ferred onto adhesive slides and dried at 62°C 
for 30 minutes. Standard heat epitope retrieval 
was performed for 30 minutes in ethylene 
diamine tetraacetic acid, pH 8.0, in the auto-
stainer. The samples were then incubated with 
primary antibodies. After incubation with pri-
mary antibodies, the sections were subse-
quently incubated with biotinylated anti-mouse 
immunoglobulins, peroxidase-labeled streptav-
idin (LSAB kit, DakoCytomation, Glostrup, 
Denmark), and 3, 30-diaminobenzidine. Nega- 
tive control samples were processed without 
the primary antibody. Slides were counter-
stained with Harris hematoxylin. Positive con-
trol tissue was used per the manufacturer’s 
recommendations.
Interpretation of immunohistochemical stain-
ing
Immunohistochemical markers were detected 
by light microscopy. The stained slides were 
evaluated semi-quantitatively using a previous-
ly reported method [8]. Tumor cell staining was 
assessed as 0: negative or weak immunostain-
ing in <1% of the tumor, 1: focal expression in 
1-10% of tumor, 2: positive in 11-50% of the 
tumor, and 3: positive in 51-100% of the tumor. 
The entire tumor area was evaluated, and a 
score of 2 or more were defined as positive. 
Statistical analysis
Data were analyzed using SPSS for Windows, 
Version 12.0 (SPSS Inc., Chicago, IL, USA). To 
determine statistical significance, Student’s t 
and Fisher’s exact tests were used for continu-
ous and categorical variables, respectively. To 
analyze data with multiple comparisons, a cor-
rected p-value with the application of Bonferroni 
multiple comparison procedure was used. 
Statistical significance was set at P<0.05. 
Kaplan-Meier survival curves and log-rank sta-
tistics were employed to evaluate time to tumor 
Table 1. Source, clone, and dilution of antibodies used in this study
Antibody Company Clone Dilution
Sarcosine metabolism-related proteins
    GNMT Abcam, Cambridge, UK Polyclonal 1:100
    SARDH Abcam, Cambridge, UK Polyclonal 1:100
    PIPOX Abcam, Cambridge, UK Polyclonal 1:100
GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase. 
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recurrence and overall survival (OS). Multivariate 
regression analysis was performed using the 
Cox proportional hazards model.
Results 
Basal characteristics of thyroid cancer
This study included 557 cases of thyroid can-
cer: 344 cases of PTC, 112 cases of FC, 70 
cases of MC, 23 cases of PDC, and eight cases 
of AC. The basal characteristics of PTC are list-
ed in Supplementary Table 1; it was composed 
of 304 cases of conventional type and 40 
cases of FVPTC. In FVPTC, the proportion of 
tumors with expanding margins (P = 0.002) was 
higher. In addition, 238 cases of PTC (69.2%) 
were found to have BRAF V600E mutation. The 
proportion of infiltrative tumor margin was high-
er (P = 0.004) in PTC with BRAF V600E muta-
tion and lower in that of FVPTC (P<0.001). FC 
was composed of 99 cases of minimally inva-
Table 2. Expression of sarcosine metabolism-related proteins according to thyroid cancer subtypes
Parameters Total N = 557 (%)
PTC
N = 344 (%)
FC
N = 112 (%)
MC
N = 70 (%)
PDC  
N = 23 (%)
AC  
N = 8 (%) P-value
GNMT n/a
    Negative 557 (100.0) 344 (100.0) 112 (100.0) 70 (100.0) 23 (100.0) 8 (100.0)
    Positive 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
SARDH <0.001
    Negative 443 (79.5) 240 (69.8) 103 (92.0) 70 (100.0) 22 (95.7) 8 (100.0)
    Positive 114 (20.5) 104 (30.2) 9 (8.0) 0 (0.0) 1 (4.3) 0 (0.0)
PIPOX <0.001
    Negative 296 (53.2) 124 (36.2) 101 (90.2) 43 (61.4) 20 (87.0) 8 (100.0)
    Positive 260 (46.8) 219 (63.8) 11 (9.8) 27 (38.6) 3 (13.0) 0 (0.0)
PTC, papillary thyroid carcinoma; FC, follicular carcinoma; MC, medullary carcinoma; PDC, poorly differentiated carcinoma; AC, 
anaplastic carcinoma; GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase. 
Figure 1. Expression of sarcosine metabolism-related proteins in thyroid cancer. Glycine N-methyltransferase 
(GNMT) was negative in all thyroid cancers. The expression of sarcosine dehydrogenase (SARDH) and pipecolic acid 
oxidase (PIPOX) was higher in PTC than in other subtypes.
Sarcosine in thyroid cancer
7135 Int J Clin Exp Pathol 2016;9(7):7132-7139
sive type and 13 cases of widely invasive type. 
In the case of widely invasive type, the propor-
conventional type (P = 0.010, and P<0.001), 
and PTC with BRAF V600E mutation showed 
Table 3. Expression of sarcosine metabolism-related proteins according to PTC histologic subtypes 
and BRAF V600E mutation status
Parameters Total N = 344 (%)
Histologic subtype
P-value
BRAF V600E mutation status
p-valueFollicular variant
N = 40 (%)
Conventional type
N = 304 (%)
No mutation 
N = 106 (%)
Mutation 
N = 238 (%)
GNMT n/a n/a
    Negative 344 (100.0) 40 (100.0) 304 (100.0) 106 (100.0) 238 (100.0)
    Positive 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
SARDH 0.010 <0.001
    Negative 240 (69.8) 35 (87.5) 205 (67.4) 101 (95.3) 139 (58.4)
    Positive 104 (30.2) 5 (12.5) 99 (32.6) 5 (4.7) 99 (41.6)
PIPOX <0.001 <0.001
    Negative 125 (36.3) 26 (65.0) 99 (32.6) 72 (67.9) 53 (22.3)
    Positive 219 (63.7) 14 (35.0) 205 (67.4) 34 (32.1) 185 (77.7)
PTC, papillary thyroid carcinoma; GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid 
oxidase. 
Figure 2. Expression of sarcosine metabolism-related proteins in PTC. 
SARDH and PIPOX expression was lower in FVPTC and PTC without BRAF 
V600E mutation.
tions of larger tumors (>2.0 cm) 
(P = 0.040), vascular invasion (P 
= 0.028), extrathyroidal involve-
ment (P<0.001), and distant me- 
tastasis (P = 0.003) were higher 
than minimally invasive type 
(Supplementary Table 2). The ba- 
sal characteristics of MC, PDC, 
and AC are described in Supple- 
mentary Table 3.
Expression of sarcosine metab-
olism-related proteins in thyroid 
cancer
We investigated the expression 
of sarcosine metabolism-related 
proteins in thyroid cancer. GNMT 
was negative in all thyroid cancer. 
The expression of SARDH and 
PIPOX varied according to thyroid 
cancer subtypes and was higher 
in PTC than in other subtypes 
(P<0.001, Table 2 and Figure 1). 
Expression of sarcosine metab-
olism-related proteins according 
to thyroid cancer subtypes
We investigated the expression 
of sarcosine metabolism-related 
proteins by thyroid cancer sub-
types. In PTC, SARDH and PIPOX 
expression varied depending on 
histologic subtypes and BRAF 
V600E mutation status. FVPTC 
showed lower expression than 
Sarcosine in thyroid cancer
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higher expression than PTC without BRAF 
V600E mutation (P<0.001, Table 3 and Figure 
2).
There were no differences in the expression of 
sarcosine metabolism-related proteins be- 
tween follicular adenoma and FC (Table 4). 
Also, there was no difference between minimal-
ly invasive and widely invasive FC (Table 5). 
When the relationship between clinicopatho-
logic factors and the expression of sarcosine 
metabolism-related proteins was reviewed in 
thyroid cancer, PIPOX positivity was associated 
with infiltrative margins in PTC (P = 0.002, 
Figure 3). 
Expression of sarcosine metabolism-related 
proteins and patient prognosis in thyroid can-
cer
We investigated the relationship between 
expression of sarcosine metabolism-related 
proteins and patient prognosis in thyroid can-
cer. In univariate analysis, PIPOX positivity was 
associated with shorter OS in PTC (P = 0.024, 
Table 6 and Figure 4). In multivariate Cox analy-
sis, lymph node metastasis was independently 
associated with shorter disease-free survival 
(hazard ratio: 6.641, 95% CI: 1.459-30.24, P = 
0.014) and age ≥45 years was associated with 
Table 4. Expression of sarcosine metabolism-related proteins in follicular neoplasms
Parameters Total N = 264 (%) Follicular adenoma N = 152 (%) Follicular carcinoma N = 112 (%) P-value
GNMT n/a
    Negative 264 (100.0) 152 (100.0) 112 (100.0)
    Positive 0 (0.0) 0 (0.0) 0 (0.0)
SARDH 0.184
    Negative 249 (94.3) 146 (96.1) 103 (92.0)
    Positive 15 (5.7) 6 (3.9) 9 (8.0)
PIPOX 0.237
    Negative 244 (92.4) 143 (94.1) 101 (90.2)
    Positive 20 (7.6) 9 (5.9) 11 (9.8)
GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase. 
Table 5. Expression of sarcosine metabolism-related proteins according to FC histologic subtypes
Parameters Total  N = 112 (%)
FC, widely invasive type  
N = 13 (%)
FC, minimally invasive type  
N = 99 (%) P-value
GNMT n/a
    Negative 112 (100.0) 13 (100.0) 99 (100.0)
    Positive 0 (0.0) 0 (0.0) 0 (0.0)
SARDH 0.595
    Negative 103 (92.0) 13 (100.0) 90 (90.9)
    Positive 9 (8.0) 0 (0.0) 9 (9.1)
PIPOX 0.614
    Negative 101 (90.2) 11 (84.6) 90 (90.9)
    Positive 11 (9.8) 2 (15.4) 9 (9.1)
FC, follicular carcinoma; GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid oxidase. 
Figure 3. Correlation between clinicopathologic fac-
tors and sarcosine metabolism-related proteins in 
PTC.
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shorter OS (hazard ratio: 14.42, 95% CI: 1.889-
110.1, P = 0.010) (Table 7).
Discussion
In this study, the expression of sarcosine 
metabolism-related proteins varied by thyroid 
cancer subtypes. SARDH and PIPOX were more 
highly expressed in PTC than in other subtypes. 
also showed that PTC with BRAF V600E muta-
tion was associated with higher expression of 
SARDH and PIPOX. In PTC with BRAF V600E 
mutation, the expression of glycolysis related 
proteins was reported to be higher in another 
study [10]. Depending on whether the BRAF 
V600E mutation is present in PTC, the meta-
bolic characteristics may vary [10]. This study 
also confirms that sarcosine metabolism-relat-
Table 6. Univariate analysis of sarcosine metabolism-related protein expression in PTC and disease-
free/overall survival using the log-rank test
Parameter Number of patients/recurrence/death 
Disease-free survival Overall survival
Mean survival 
(95% CI) months P-value
Mean survival 
(95% CI) months P-value
GNMT n/a n/a
    Negative 344/18/18 n/a n/a
    Positive 0/0/0 n/a n/a
SARDH 0.871 0.118
    Negative 240/13/10 106 (103-108) 108 (106-110)
    Positive 104/5/8 107 (103-111) 105 (100-109)
PIPOX 0.488 0.024
    Negative 125/8/2 106 (102-110) 111 (109-112)
    Positive 219/10/16 107 (105-110) 106 (103-109)
PTC, papillary thyroid carcinoma; GNMT, glycine N-methyltransferase; SARDH, sarcosine dehydrogenase; PIPOX, l-pipecolic acid 
oxidase. 
Figure 4. Expression of sarcosine metabolism-related proteins and patient 
prognosis in PTC.
Direct comparison with other 
research is not possible be- 
cause there are few other stud-
ies on sarcosine metabolism in 
thyroid cancer. However, similar 
differences in PIPOX expression 
between invasive ductal carci-
noma and invasive lobular car-
cinoma of breast cancer have 
been reported [9]. Although tu- 
mors may originate from the 
same cell type, different expres-
sion can be seen depending on 
the histologic subtypes. In fact, 
in thyroid cancer, the expres-
sion of SARDH and PIPOX was 
lower in FVPTC than in conven-
tional PTC. SARDH and PIPOX 
expression was highest in con-
ventional PTC followed by FVP- 
TC and FC; therefore, SARDH 
and PIPOX were proven to show 
lower expression and more fol-
licular differentiation. Further 
investigation regarding the bio-
logic significance of these find-
ings will be required. This study 
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ed proteins are more highly expressed in PTC 
with BRAF V600E mutation. The possible 
mechanism was raised why PTC with BRAF 
V600E mutation showing high metabolic activ-
ity. It is that BRAF mutation activates mitogen-
activated protein kinase downstream targets 
such as c-myc and HIF-1a and thereby increas-
es glucose metabolism [11, 12]. Further stud-
ies on the association of sarcosine metabo-
lism-related proteins and PTC with BRAF V600E 
mutation seem to be necessary.
In this study, the expression of SARDH was not 
shown in MC; in contrast, the expression of 
PIPOX had a large percentage in MC next to PTC 
(38.6%). The mechanism by which PIPOX is 
expressed in MC is unknown. However, the 
association between PIPOX and HER-2 can be 
considered a possible cause. Because it has 
been previously reported that the expression of 
HER-2 is higher in MC [13] and the expression 
of PIPOX has been found to be associated with 
HER-2 positivity in breast cancer [6, 14], further 
studies on the relationship between HER-2 and 
PIPOX in MC are needed. 
In this study, the expression of PIPOX was found 
to be associated with poor prognosis in PTC. 
The expression of PIPOX in metastatic breast 
cancer was also associated with poor progno-
sis, which is compatible with the results of this 
study [15]. In contrast, PIPOX negativity was 
reported to be associated with a poor progno-
sis in primary breast cancer [6]. The mecha-
nism and utility of PIPOX as a prognostic mark-
er thus warrants further investigation.
In conclusion, the expression of sarcosine 
metabolism-related proteins varied according 
to thyroid cancer subtypes. SARDH and PIPOX 
were highly expressed in PTC. Among the PTC 
subtypes, there was lower expression of SARDH 
and PIPOX in FVPTC and higher expression in 
PTC with BRAF V600E mutation. 
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Table 7. Multivariate analysis of PTC survival 
Included parameters
Disease-free survival Overall survival
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age (years) 0.620 0.010
    <45 versus ≥45 1.276 0.488-3.338 14.42 1.889-110.1
Tumor size (cm) 0.828 0.133
    ≤2.0 versus >2.0 1.124 0.392-3.222 2.161 0.792-5.901
Tumor extension 0.278 0.466
    Intrathyroidal versus extrathyroidal 0.583 0.220-1.544 0.675 0.235-1.942
Histologic type 0.634 n/a
    Follicular versus conventional 1.449 0.315-6.658 n/a n/a
Lymph node metastasis 0.014 0.092
    No versus yes 6.641 1.459-30.24 2.626 0.854-8.069
BRAF V600E mutation 0.381 n/a
    No versus yes 0.612 0.204-1.839 n/a n/a
PIPOX 0.601 0.301
    Negative versus positive 0.757 0.267-2.149 2.182 0.198-9.555
PTC, papillary thyroid carcinoma; PIPOX, l-pipecolic acid oxidase. 
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Supplementary Table 1. Basal characteristics of PTC
Parameters Total N = 344 (%)
Histologic subtype
P-
value
BRAF V600E mutation 
status
P-value
Conventional type
N = 304 (%)
Follicular variant
N = 40 (%)
No mutation 
N = 106 (%)
Mutation 
N = 238 (%)
Age (years) 0.741 0.089
    <45 155 (45.1) 136 (44.7) 19 (47.5) 55 (51.9) 100 (42.0)
    ≥45 189 (54.9) 168 (55.3) 21 (52.5) 51 (48.1) 138 (58.0)
Sex 0.969 0.235
    Male 68 (19.8) 60 (19.7) 8 (20.0) 25 (23.6) 43 (18.1)
    Female 276 (80.2) 244 (80.3) 32 (80.0) 81 (76.4) 195 (81.9)
Tumor size (cm) 0.951 0.506
    ≤2.0 272 (79.1) 240 (78.9) 32 (80.0) 80 (75.5) 192 (80.7)
    >2.0, ≤4.0 65 (18.9) 58 (19.1) 7 (17.5) 23 (21.7) 42 (17.6)
    >4.0 7 (2.0) 6 (2.0) 1 (2.5) 3 (2.8) 4 (1.7)
Tumor margin 0.002 0.004
    Infiltrative 289 (84.0) 262 (67.5) 27 (67.5) 80 (75.5) 209 (87.8)
    Expanding 55 (16.0) 42 (13.8) 13 (32.5) 26 (24.5) 29 (12.2)
Tumor extension 0.330 0.177
    Intrathyroidal 106 (30.8) 91 (29.9) 15 (37.5) 38 (35.8) 68 (28.6)
    Extrathyroidal 238 (69.2) 213 (70.1) 25 (62.5) 68 (64.2) 170 (71.4)
Histologic subtype <0.001
    Conventional 81 (76.4) 223 (93.7)
    Follicular 25 (23.6) 15 (6.3)
LN metastasis 0.175 0.075
    No 138 (40.1) 118 (38.8) 20 (50.0) 50 (47.2) 88 (37.0)
    Yes 206 (59.9) 186 (61.2) 20 (50.0) 56 (52.8) 150 (63.0)
Distant metastasis 0.944 0.446
    No 326 (94.8) 288 (94.7) 38 (95.0) 99 (93.4) 227 (95.4)
    Yes 18 (5.2) 16 (5.3) 2 (5.0) 7 (6.6) 11 (4.6)
PTC, papillary thyroid carcinoma.
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Supplementary Table 2. Basal characteristics of FC
Parameters Total N = 112 (%)
FC, minimally invasive type
N = 99 (%)
FC, widely invasive type
N = 13 (%) P-value
Age (years) 0.255
    <45 51 (45.5) 47 (47.5) 4 (30.8)
    ≥45 61 (54.5) 52 (52.5) 9 (69.2)
Sex 0.233
    Male 28 (25.0) 23 (23.2) 5 (38.5)
    Female 84 (75.0) 76 (76.8) 8 (61.5)
Tumor size (cm) 0.040
    ≤2.0 34 (30.4) 34 (34.3) 0 (0.0)
    >2.0, ≤4.0 49 (43.8) 41 (41.4) 8 (61.5)
    >4.0 29 (25.9) 24 (24.2) 5 (38.5)
Capsular invasion 0.147
    No 14 (12.5) 14 (14.1) 0 (0.0)
    Yes 98 (87.5) 85 (85.9) 13 (100.0)
Vascular invasion 0.028
    No 66 (58.9) 62 (62.6) 4 (30.8)
    Yes 46 (41.1) 37 (37.4) 9 (69.2)
Tumor extension <0.001
    Intrathyroidal 95 (84.8) 89 (89.9) 6 (46.2)
    Extrathyroidal 17 (15.2) 10 (10.1) 7 (53.8)
LN metastasis 0.220
    No 110 (98.2) 98 (99.0) 12 (92.3)
    Yes 2 (1.8) 1 (1.0) 1 (7.7)
Distant metastasis 0.003
    No 101 (90.2) 93 (93.9) 8 (61.5)
    Yes 11 (9.8) 6 (6.1) 5 (38.5)
FC: follicular carcinoma.
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Supplementary Table 3. Basal characteristics of MC, PDC, 
and AC
Parameters MC, n = 70 (%) PDC, n = 23 (%) AC, n = 8 (%)
Age (years)
    <45 21 (30.0) 4 (17.4) 0 (0.0)
    ≥45 49 (70.0) 19 (82.6) 8 (100.0)
Sex 
    Male 22 (31.4) 10 (43.5) 1 (12.5)
    Female 48 (68.6) 13 (56.5) 7 (87.5)
Tumor size (cm)
    ≤2.0 53 (75.7) 8 (34.8) 0 (0.0)
    >2.0, ≤4.0 14 (20.0) 9 (39.1) 1 (12.5)
    >4.0 3 (4.3) 6 (26.1) 7 (87.5)
Tumor margin
    Infiltrative 45 (64.3) 17 (73.9) 8 (100.0)
    Expanding 25 (35.7) 6 (26.1) 0 (0.0)
Tumor extension
    Intrathyroidal 52 (74.3) 11 (47.8) 0 (0.0)
    Extrathyroidal 18 (25.7) 12 (52.2) 8 (100.0)
LN metastasis
    No 47 (67.1) 22 (95.7) 4 (50.0)
    Yes 23 (32.9) 1 (4.3) 4 (50.0)
Distant metastasis
    No 67 (95.7) 16 (69.6) 8 (100.0)
    Yes 3 (4.3) 7 (30.4) 0 (0.0)
MC, medullary carcinoma; PDC, poorly differentiated carcinoma; AC, ana-
plastic carcinoma.
